+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Radiodermatitis Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017-2024

  • ID: 4852026
  • Report
  • April 2018
  • Region: Global
  • 154 pages
  • Transparency Market Research
1 of 2

Global Radiodermatitis Market: Overview

Radiodermatitis, also known as radiation dermatitis, is a peculiar symptom caused as a result of radiation therapy pertaining to the treatment of cancerous as well as noncancerous conditions, and has significant negative impact on a patient’s physical functionalities and quality of life. It has been estimated that in developed countries such as the U.S., Canada, Australia, the U.K, France, and Germany, nearly half of the patients who receive treatment for cancer was also subjected to radiation therapy during the illness, and about all of them experience some degree of skin reaction. As the cases of cancer escalates across the world, the demand in the global radiodermatitis is expected to increment at a considerable CAGR of 3.93% during the forecast period of 2017 to 2024. 

This report, developed by a group of professional market research analysts, aspires to serve as a credible business tool for the stakeholders of this market. The report studies the prospects of various segments of the market, based on product, distribution channel, and geography, as well as profiles a number of leading players to understand the competitive landscape. Qualitative and quantitative assessment of all factors that may influence the demand for radiodermatitis has been provided in the report. 

Global Radiodermatitis Market: Trends & Opportunities

According to the International Agency for Research on Cancer (IARC), there were 14.1 million new cases of cancer across the world, and the figure is estimated to reach up to 21.7 million by the end of 2030. This substantial patient volume is the primary driver of the global radiodermatitis market. In addition to that, increasing focus on product innovation as well as advancements in the existing products are also expected to favor the market in the near future. Growing number of private and public healthcare organizations, who are constantly trying to promote the awareness regarding radiodermatitis treatment and management, and rising number of clinical studies to evaluate the efficiency of radiodermatitis treatment are some of the other factors favoring the global radiodermatitis market. 

Based on product, the global radiodermatitis market has been segmented into topical, oral medication, and dressings. While topical segment is sub-segmented into hydrophilic creams, corticosteroids, and others such as antibiotics, oral medical is further divided into corticosteroids and others such as antibiotics and oral analgesics, whereas dressing segment is further categorized into hydrogel, no sting barrier film, hydrocolloid, honey impregnated gauze, silicone coated dressing, and others such as silver leaf dressing and GM-CSF gauze. On the basis of dressing channel, the market has been bifurcated into hospital pharmacy, online store, and retail pharmacy store.

Global Radiodermatitis Market: Regional Outlook

Though the demand for radiodermatitis is growing in all regions across the globe, Asia Pacific currently serves the maximum demand, owing to higher percentage untapped patient-base. A number of emerging economies in the Asian region are situated in tropical region with humid weather conditions, in which the effect of radiation dermatitis is quite high. Extensive collaborations among the key players in order to increase their product portfolio and involvement of well-established pharmaceutical companies in this region on commercialization of their products are also expected to help them increment their shares in this region. 

Companies mentioned in the research report

Smith & Nephew plc, 3M Healthcare, Acelity, Convatec, Inc., and Molnlycke Health Care are some of the key companies operating in this market.

This report gives you access to decisive data such as:

  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for the coming years 

Key highlights of this report

  • Overview of key market forces propelling and restraining market growth
  • Up-to-date analyses of market trends and technological improvements
  • Pin-point analyses of market competition dynamics to offer you a competitive edge
  • An analysis of strategies of major competitors
  • An array of graphics and SWOT analysis of major industry segments
  • Detailed analyses of industry trends
  • A well-defined technological growth map with an impact-analysis
  • Offers a clear understanding of the competitive landscape and key product segments
Note: Product cover images may vary from those shown
2 of 2
Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary: Global Radiodermatitis Market

Chapter 4. Market Overview
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunity
4.3. Value Chain Analysis

Chapter 5. Global Radiodermatitis Market Analysis and Forecast, by Product
5.1. Key Findings
5.2. Introduction
5.3. Market Size (US$ Mn) Forecast, by Product
5.3.1. Topical
5.3.1.1. Corticosteroids
5.3.1.2. Hydrophilic Creams
5.3.1.3. Others (topical antibiotics)
5.3.2. Oral Medication
5.3.2.1. Corticosteroids
5.3.2.2. Others (analgesics, antibiotics, etc.)
5.3.3. Dressings
5.3.3.1. Hydrogel
5.3.3.2. Hydrocolloid
5.3.3.3. No Sting Barrier Film
5.3.3.4. Honey Impregnated Gauze
5.3.3.5. Silicone Coated Dressing
5.3.3.6. Others (silver leaf dressings, GM-CSF gauze, etc.)
5.4. Market Attractiveness Analysis, by Product, 2015
5.5. Key Trends

Chapter 6. Global Radiodermatitis Market Analysis and Forecast, by Distribution Channel
6.1. Key Findings
6.2. Introduction
6.3. Market Size (US$ Mn) Forecast, by Distribution Channel
6.3.1. Hospital Pharmacy
6.3.2. Retail Pharmacy Store
6.3.3. Online Store
6.4. Market Attractiveness Analysis, by Distribution Channel, 2015

Chapter 7. Pipeline Analysis
7.1. List of discontinued trials
7.2. Clinical trial data for open studies

Chapter 8. Global Radiodermatitis Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Introduction
8.3. Market Size (US$ Mn) Forecast, by Region
8.3.1. North America
8.3.2. Europe
8.3.3. Asia Pacific
8.3.4. Latin America
8.3.5. Middle East & Africa
8.4. Market Attractiveness Analysis, by Region, 2015
8.5. Key Trends

Chapter 9. North America Radiodermatitis Market Analysis and Forecast
9.1. Key Findings
9.2. Introduction
9.3. Market Size (US$ Mn) Forecast, by Product
9.3.1. Topical
9.3.2. Oral Medication
9.3.3. Dressings
9.4. Market Size (US$ Mn) Forecast, by Distribution Channel
9.4.1. Hospital Pharmacy
9.4.2. Retail Pharmacy Store
9.4.3. Online Store
9.5. Market Size (US$ Mn) Forecast, by Country
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis, by Product, 2015
9.7. Market Attractiveness Analysis, by Distribution Channel, 2015
9.8. Key Trends

Chapter 10. Europe Radiodermatitis Market Analysis and Forecast
10.1. Key Findings
10.2. Introduction
10.3. Market Size (US$ Mn) Forecast, by Product
10.3.1. Topical
10.3.2. Oral Medication
10.3.3. Dressings
10.4. Market Size (US$ Mn) Forecast, by Distribution Channel
10.4.1. Hospital Pharmacy
10.4.2. Retail Pharmacy Store
10.4.3. Online Store
10.5. Market Size (US$ Mn) Forecast, by Country
10.5.1. U.K.
10.5.2. Germany
10.5.3. Rest of Europe
10.6. Market Attractiveness Analysis, by Product, 2015
10.7. Market Attractiveness Analysis, by Distribution Channel, 2015
10.8. Key Trends

Chapter 11. Asia Pacific Radiodermatitis Market Analysis and Forecast
11.1. Key Findings
11.2. Introduction
11.3. Market Size (US$ Mn) Forecast, by Product
11.3.1. Topical
11.3.2. Oral Medication
11.3.3. Dressings
11.4. Market Size (US$ Mn) Forecast, by Distribution Channel
11.4.1. Hospital Pharmacy
11.4.2. Retail Pharmacy Store
11.4.3. Online Store
11.5. Market Size (US$ Mn) Forecast, by Country
11.5.1. China
11.5.2. Japan
11.5.3. Rest of Asia Pacific
11.6. Market Attractiveness Analysis, by Product, 2015
11.7. Market Attractiveness Analysis, by Distribution Channel, 2015
11.8. Key Trends

Chapter 12. Latin America Radiodermatitis Market Analysis and Forecast
12.1. Key Findings
12.2. Introduction
12.3. Market Size (US$ Mn) Forecast, by Product
12.3.1. Topical
12.3.2. Oral Medication
12.3.3. Dressings
12.4. Market Size (US$ Mn) Forecast, by Distribution Channel
12.4.1. Hospital Pharmacy
12.4.2. Retail Pharmacy Store
12.4.3. Online Store
12.5. Market Size (US$ Mn) Forecast, by Country
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis, by Product, 2015
12.7. Market Attractiveness Analysis, by Distribution Channel, 2015
12.8. Key Trends

Chapter 13. Middle East & Africa Radiodermatitis Market Analysis and Forecast
13.1. Key Findings
13.2. Introduction
13.3. Market Size (US$ Mn) Forecast, by Product
13.3.1. Topical
13.3.2. Oral Medication
13.3.3. Dressings
13.4. Market Size (US$ Mn) Forecast, by Distribution Channel
13.4.1. Hospital Pharmacy
13.4.2. Retail Pharmacy Store
13.4.3. Online Store
13.5. Market Size (US$ Mn) Forecast, by Country
13.5.1. UAE
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis, by Product, 2015
13.7. Market Attractiveness Analysis, by Distribution Channel, 2015
13.8. Key Trends

Chapter 14. Competition Landscape
14.1. Market Share Analysis
14.2. Competition Matrix
14.3. Company Profiles
14.3.1. 3M
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Financial Overview
14.3.1.3. Product Portfolio
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Acelity LP, Inc.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Financial Overview
14.3.2.3. Product Portfolio
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. BMG Pharma S.r.l.
14.3.3.1. Company Overview (HQ, business segments, employee strength)
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Recent Developments
14.3.3.5. Strategic Overview
14.3.4. ConvaTec, Inc.
14.3.4.1. Company Overview (HQ, business segments, employee strength)
14.3.4.2. Financial Overview
14.3.4.3. Product Portfolio
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Derma Sciences Inc.
14.3.5.1. Company Overview (HQ, business segments, employee strength)
14.3.5.2. Financial Overview
14.3.5.3. Product Portfolio
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Intermed Pharmaceuticals
14.3.6.1. Company Overview (HQ, business segments, employee strength)
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Recent Developments
14.3.6.5. Strategic Overview
14.3.7. Molnlycke Health Care
14.3.7.1. Company Overview (HQ, business segments, employee strength)
14.3.7.2. Financial Overview
14.3.7.3. Product Portfolio
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Smith & Nephew plc
14.3.8.1. Company Overview (HQ, business segments, employee strength)
14.3.8.2. Financial Overview
14.3.8.3. Product Portfolio
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. Stratpharma AG
14.3.9.1. Company Overview (HQ, business segments, employee strength)
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Strategic Overview
14.3.9.5. Value Chain
14.3.10. Others
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll